TrialLeukemia2024

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.

Gianantonio Rosti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.